NasdaqGS:SYREBiotechs
Spyre Therapeutics (SYRE) Is Up 16.5% After Strong Phase 2 SKYLINE Data in Ulcerative Colitis
Spyre Therapeutics recently reported positive initial 12-week induction topline results from Part A of its Phase 2 SKYLINE trial, where SPY002 met its primary histopathology endpoint and achieved meaningful clinical remission and endoscopic improvement in moderately-to-severely active ulcerative colitis with a tolerability profile in line with the TL1A class.
An interesting aspect of the data is that these outcomes were achieved in a relatively challenging patient group, including over...

